Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing. The etiology of this illness is rather complex and not completely known but deposits of aberrant β- amyloid protein, as well as τ-protein hyperphosphorylation, oxidative stress, dyshomeostasis of biometals and low levels of acetylcholine (ACh) seem to play a significant role. Such complex etiology of AD has encouraged active research in the development of multi-target drugs with two or more complementary biological activities, since they may represent an important advance in the treatment of this disease. Dual inhibitors combining anti-acetyl cholinesterase (AChE) and antimonoamine oxidase (MAO) activities in one molecular entity have been recently reported. Inhibition of AChE increases neurotransmission at cholinergic synapses and reduce temporally the cognitive deficit. AChE also participates in other functions related to neuronal development, differentiation, adhesion and β-amyloid protein processing. In addition MAOB inhibition retards further deterioration of cognitive functions. In this review relevant aspects about structure, mechanism and pharmacological effects of these dual inhibitors are reported.
Keywords: Neurodegenerative disorders, Alzheimer disease, multi-target drugs, cholinesterase inhibitors, monoamine oxidase inhibitors.
Current Topics in Medicinal Chemistry
Title:Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease
Volume: 13 Issue: 14
Author(s): Matilde Yanez and Dolores Vina
Affiliation:
Keywords: Neurodegenerative disorders, Alzheimer disease, multi-target drugs, cholinesterase inhibitors, monoamine oxidase inhibitors.
Abstract: Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing. The etiology of this illness is rather complex and not completely known but deposits of aberrant β- amyloid protein, as well as τ-protein hyperphosphorylation, oxidative stress, dyshomeostasis of biometals and low levels of acetylcholine (ACh) seem to play a significant role. Such complex etiology of AD has encouraged active research in the development of multi-target drugs with two or more complementary biological activities, since they may represent an important advance in the treatment of this disease. Dual inhibitors combining anti-acetyl cholinesterase (AChE) and antimonoamine oxidase (MAO) activities in one molecular entity have been recently reported. Inhibition of AChE increases neurotransmission at cholinergic synapses and reduce temporally the cognitive deficit. AChE also participates in other functions related to neuronal development, differentiation, adhesion and β-amyloid protein processing. In addition MAOB inhibition retards further deterioration of cognitive functions. In this review relevant aspects about structure, mechanism and pharmacological effects of these dual inhibitors are reported.
Export Options
About this article
Cite this article as:
Yanez Matilde and Vina Dolores, Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease, Current Topics in Medicinal Chemistry 2013; 13 (14) . https://dx.doi.org/10.2174/15680266113139990120
DOI https://dx.doi.org/10.2174/15680266113139990120 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Cell Therapies for IBD: What Works?
Current Drug Targets CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloidbeta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro
Current Alzheimer Research Neuroprotective Effect of Resveratrol Against Methamphetamine-Induced Dopaminergic Apoptotic Cell Death in a Cell Culture Model of Neurotoxicity
Current Neuropharmacology Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology Curcumin Activates the Nrf2 Pathway and Induces Cellular Protection Against Oxidative Injury
Current Molecular Medicine Environmental Enrichment as a Positive Behavioral Intervention Across the Lifespan
Current Neuropharmacology Anti-Inflammatory Therapy for Alzheimer’s Disease from Epidemiological Fact to New Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Trends and Applications of Brain Computer Interfaces
Current Signal Transduction Therapy Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
Current Pharmaceutical Design Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug
Current Topics in Medicinal Chemistry Alzheimer’s Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Direct Covalent Modification as a Strategy to Inhibit Nuclear Factor-Kappa B
Current Medicinal Chemistry Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice
Current Alzheimer Research Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Molecular Imaging of Stem Cell Transplantation for Neurodegenerative Diseases
Current Pharmaceutical Design